SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $16.76 million for the quarter. SOPHiA GENETICS has set its FY 2025 guidance at EPS.
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The firm had revenue of $17.73 million for the quarter, compared to the consensus estimate of $17.71 million. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
SOPHiA GENETICS Price Performance
NASDAQ:SOPH opened at $3.12 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. The company has a 50-day moving average of $3.18 and a 200-day moving average of $3.37. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $6.28. The company has a market capitalization of $208.06 million, a price-to-earnings ratio of -2.86 and a beta of 1.02.
Analysts Set New Price Targets
Check Out Our Latest Report on SOPHiA GENETICS
SOPHiA GENETICS Company Profile
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Further Reading
- Five stocks we like better than SOPHiA GENETICS
- Insider Selling Explained: Can it Inform Your Investing Choices?
- T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip
- Insider Trades May Not Tell You What You Think
- 3M Stock: 4 Compelling Reasons to Buy, 1 Big Reason to Pass
- There Are Different Types of Stock To Invest In
- Kroger: This Must-Own Staples Stock Thrives in Every Market
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.